Nasdaq
$182.28▼ 2.55%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $38.75BShares out 2.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
43- 10.13After-hours26.10.14 05:328-KKey event#●●●#●●●#●●●
Revolution Medicines, Inc.
Revolution Medicines has drawn down a $250 million Tranche A loan from Royalty Pharma following the FDA approval of RASONQUE. Additionally, the company elected not to exercise its option for the Tranche 3 royalty purchase agreement, opting out of that specific $250 million funding opportunity.…more
$182.28-2.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1After-hours26.10.02 07:004Ownership
Revolution Medicines, Inc.
Insider Alan B. Sandler of Revolution Medicines, Inc. filed a Form 4 statement of changes in beneficial ownership of securities on September 29, 2026. This filing officially records the changes in the insider's equity holdings.…more
$182.28-2.55%vs prev closeView filingShare - 9.29After-hours26.09.30 07:004Ownership
Revolution Medicines, Inc.
Jeff Cislini of Revolution Medicines, Inc. filed a Form 4 on September 29, 2026, reporting a change in beneficial ownership of securities effective September 25, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$182.28-2.55%vs prev closeView filingShare
42 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.24 00:36#●●●#●●●
Tango Therapeutics Shares Fall Despite Positive Cancer Drug Data
Tango Therapeutics reported strong efficacy for its vopimetostat combination in pancreatic and lung cancer trials, yet the stock declined following the announcement. The company plans to initiate a global registrational Phase 3 trial for first-line pancreatic cancer treatment in the first half of 2027.…more
$182.28-2.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoPre-market26.10.23 20:30
●●●●●●●● ●●●●● ●●●●●●
Revolution Medicines presented exploratory subgroup analyses from the Phase 3 RASolute 302 trial at ESMO 2026, demonstrating consistent overall survival benefits of RASONQUE compared to chemotherapy. The findings reinforce the drug's potential as a standard of care across diverse patient subgroups, including those with various RAS mutations.…more
$182.28-2.55%vs prev close - 3d agoAfter-hours26.10.22 05:05
●●●●●●●● ●●●●● ●●●●●●
Revolution Medicines announced it will release its third-quarter 2026 financial results after the market closes on November 4, 2026. Management will host a webcast following the release to discuss the quarterly performance and provide corporate updates.…more
$182.28-2.55%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report